



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

UT481 : Endometrium cancer tissue array, including TNM and pathology grade, 48 cases/48 cores

Microarray Panel	Endometrium carcinoma tissue microarray, containing 48 cases of adenocarcinoma, single core per case		
Cores	48		
Cases	48		
Row number	6		
Column number	8		
Core Diameter (mm)	2		
Thickness (µm)	5		
QA/QC	Anti-Actin confirmed		
Tissue Array Type	FFPE		
Species	Human		
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.		
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, “*” means invalid core; “-” means no applicable or negative in IHC markers.		

	1	2	3	4	5	6	7	8
A	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
B	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
C	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
D	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
E	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute
F	Ute	Ute	Ute	Ute	Ute	Ute	Ute	Ute

Legend: Ute - Uterus

 - Malignant tumor,
  - Malignant tumor (stage I),
  - Malignant tumor (stage II),
  - Malignant tumor (stage IIIa),
  - Malignant tumor (stage IIb),
  - Malignant tumor (stage Ia),
  - Malignant tumor (stage Ib),
  - Malignant tumor (stage Ic)

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	60	F	Uterus	Endometrioid adenocarcinoma	T2N0M0	1	II	malignant	
A2	2	56	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
A3	3	53	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant	
A4	4	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
A5	5	44	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
A6	6	50	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant	
A7	7	63	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
A8	8	65	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
B1	9	63	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	1	Ia	malignant	
B2	10	50	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
B3	11	54	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	

B4	12	48	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
B5	13	50	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant	
B6	14	40	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	1	Ia	malignant	
B7	15	55	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant	
B8	16	63	F	Uterus	Endometrioid adenocarcinoma	T2bN0M0	1	IIb	malignant	
C1	17	33	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
C2	18	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
C3	19	56	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	2	Ia	malignant	
C4	20	68	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
C5	21	42	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2--3	Ic	malignant	
C6	22	46	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
C7	23	62	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
C8	24	52	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
D1	25	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
D2	26	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
D3	27	53	F	Uterus	Endometrioid adenocarcinoma (sparse)	T1bN0M0	1	Ib	malignant	
D4	28	70	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
D5	29	53	F	Uterus	Endometrioid adenocarcinoma	T1N0M0	3	I	malignant	
D6	30	54	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
D7	31	30	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
D8	32	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	-	Ib	malignant	
E1	33	43	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
E2	34	58	F	Uterus	Endometrioid adenocarcinoma (sparse)	T1cN0M0	2	Ic	malignant	
E3	35	54	F	Uterus	Endometrioid adenocarcinoma	T2N0M0	2	II	malignant	
E4	36	44	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	2	IIa	malignant	
E5	37	66	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	2	IIa	malignant	
E6	38	51	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	2	IIa	malignant	
E7	39	52	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
E8	40	70	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
F1	41	55	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2--3	Ib	malignant	
F2	42	62	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2--3	Ic	malignant	
F3	43	36	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	3	Ib	malignant	
F4	44	43	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant	
F5	45	63	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	3	Ib	malignant	
F6	46	74	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant	
F7	47	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant	
F8	48	51	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	3	IIa	malignant	
-	0	58	M	Skin	Malignant melanoma (tissue marker)		-		Malignant	

◀		▶
---	--	---

TNM grading:

T - Primary tumor

Tx - Primary tumor cannot be assessed

T0 - No evidence of primary tumor

Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria

T1 - Tumor invades submucosa

T2 - Tumor invades muscularis propria

T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.

T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

Nx - Regional lymph nodes cannot be assessed

N0 - No regional lymph node metastasis

N1 - Metastasis in 1 to 3 regional lymph nodes

N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis

Mx - Distant metastasis cannot be assessed

M0 - No distant metastasis
M1 - Distant metastasis

AMSBIO | www.amsbio.com | info@amsbio.com

 **UK & Rest of the World**
184 Park Drive, Milton Park
Abingdon OX14 4SE, U.K.
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482

 **North America**
1035 Cambridge Street,
Cambridge, MA 02141.
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

 **Germany**
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880

 **Switzerland**
Via Lisano 3
(CP.683)
6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85